Table 4.
Prevalence of Any HPV and Vaccine-Type HPV in Anal and/or Oral Specimens, by HPV Vaccination History among Participating Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men
| Total | Any HPV Type | ≥1 4vHPV Type | |||||
|---|---|---|---|---|---|---|---|
| HPV Vaccination History | N | n (%) | PR (95% CI) | aPR* (95% CI) | n (%) | PR (95% CI) | aPR* (95% CI) |
| No HPV vaccine doses | 687 | 474 (69.0) | Ref | Ref | 217 (31.6) | Ref | Ref |
| ≥1 HPV vaccine dose | 704 | 510 (72.4) | 1.05 (0.98–1.12) | 1.01 (0.96–1.05) | 161 (22.9) | 0.72 (0.60–0.85) | 0.71 (0.59–0.83) |
| First dose at age ≤18 years | 289 | 169 (58.5) | 0.85 (0.75–0.94) | 0.90 (0.80–1.00) | 32 (11.1) | 0.35 (0.23–0.47) | 0.41 (0.24–0.57) |
| First dose at age >18 years | 366 | 306 (83.6) | 1.21 (1.13–1.29) | 1.10 (1.00–1.19) | 118 (32.2) | 1.02 (0.83–1.21) | 0.82 (0.67–0.98) |
Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; HPV, human papillomavirus; PR, prevalence ratio; Ref, reference; 4vHPV, quadrivalent HPV vaccine.
NOTE: Bold font indicates significance at P < .05.
*Adjusted for age, race/ethnicity, city, number of sex partners, and HIV status.